Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib

Phase 1CompletedNCT00700687

POZEN90 enrolled

Overview

We will evaluate the effect on the gastroduodenal mucosa from oral dosing of three different treatments

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

PA32540DRUG

aspirin/omeprazole

PA32540 and celecoxibDRUG

aspirin/omeprazole and celecoxib

aspirin and [NSAID]DRUG

aspirin and \[NSAID\]

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male or non-pregnant female subjects greater than or equal to 50 years as well as other standard inclusion criteria for a study of this nature Exclusion Criteria: * Standard exclusion criteria for a study of this nature

Locations (1)

Unnamed facility

Anaheim, California, United States

Outcomes

Primary Outcomes

Lanza scores

Time frame: entire course of study

Secondary Outcomes

safety of three treatments

Time frame: entrie course of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.